GE HealthCare has deepened its partnership with DeepHealth to expand access to AI-powered breast cancer screening solutions, aiming to improve early detection and streamline imaging workflows globally.
Glimpse:
Announced in April 2026, GE HealthCare expanded its collaboration with DeepHealth (a RadNet subsidiary) to integrate advanced AI tools into mammography systems. The partnership includes solutions like ProFound Pro and Safeguard Review, designed to enhance cancer detection, automate workflows, and improve diagnostic accuracy.
GE HealthCare has strengthened its collaboration with DeepHealth to accelerate the adoption of AI-powered breast cancer screening technologies across global healthcare systems. The expanded partnership builds on an earlier 2024 agreement that combined DeepHealth’s AI-driven screening workflow with GE HealthCare’s Senographe Pristina mammography platform.
The latest phase of the collaboration focuses on expanding access to DeepHealth’s Breast Suite, a cloud-based platform of modular AI applications that integrate seamlessly into existing imaging workflows. These tools are designed to assist radiologists in detecting abnormalities, improving efficiency, and enabling more consistent diagnostic outcomes.
Key additions to the platform include ProFound Pro, which uses AI for lesion detection and automated breast density assessment, and Safeguard Review, a workflow tool that flags complex cases requiring further evaluation. These solutions aim to enhance clinical decision making and reduce the risk of missed diagnoses.
The integration of DeepHealth’s AI tools with GE HealthCare’s Pristina Via mammography system enables scalable, high-efficiency screening programs. The combined system supports workflow automation, real time alerts, and improved image interpretation, helping clinicians detect breast cancer earlier and with greater confidence.
Clinical studies have demonstrated significant impact, with AI-driven workflows showing up to a 21% increase in breast cancer detection rates compared to standard screening methods. The benefits are even more pronounced in women with dense breast tissue, a group where detection is traditionally more challenging.
The collaboration also aims to expand these capabilities internationally, making advanced AI-driven screening tools accessible to more healthcare providers and patients worldwide.
Overall, the partnership reflects a growing shift toward AI-enabled precision diagnostics, where advanced imaging technologies are used to improve early detection, reduce workload on radiologists, and enhance patient outcomes in breast cancer care.
“By integrating Breast Suite AI we’re helping clinicians detect breast cancer early with greater confidence.”
By
HB Team
